Effects of CYP2C9 polymorphism on the pharmacokinetics of irbesartan in healthy Korean subjects

被引：0
|
作者：
Kim, Mi-Jung
Bae, Jung -Woo
Han, Ho-Kyun
Choi, Sun-Ok
Kim, Ok-Hee
Jang, Choon-Gon
Lee, Jin-Hee
Kim, Nam-Tae
Lee, Seok-Yong
机构：
[1] Sungkyunkwan Univ, Coll Pharm, Seoul, South Korea
[2] Natl Inst Toxicol Res, Seoul, South Korea
来源：
ACTA PHARMACOLOGICA SINICA | 2006年 / 27卷
关键词：
Irbesartan; CYP2C9; polymorphism; pharmacokinetics;
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：231 / 231
页数：1
相关论文
共 50 条
  • [31] Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocournon in healthy volunteers
    Kirchheiner, J
    Ufer, M
    Walter, EC
    Kammerer, B
    Kahlich, R
    Meisel, C
    Schwab, M
    Gleiter, CH
    Rane, A
    Roots, I
    Brockmöller, J
    PHARMACOGENETICS, 2004, 14 (01): : 19 - 26
  • [32] Significance of CYP2C9 genetic polymorphism in inhibitory effect of Δ9-tetrahydrocannabinol on CYP2C9 activity
    Satoshi Yamaori
    Mika Kushihara
    Kyoko Koeda
    Ikuo Yamamoto
    Kazuhito Watanabe
    Forensic Toxicology, 2013, 31 : 70 - 75
  • [33] CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population
    Hong, XM
    Zhang, SC
    Mao, GY
    Jiang, SQ
    Zhang, Y
    Yu, YX
    Tang, GF
    Xing, HX
    Xu, XP
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (09) : 627 - 634
  • [34] Significance of CYP2C9 genetic polymorphism in inhibitory effect of Δ9-tetrahydrocannabinol on CYP2C9 activity
    Yamaori, Satoshi
    Kushihara, Mika
    Koeda, Kyoko
    Yamamoto, Ikuo
    Watanabe, Kazuhito
    FORENSIC TOXICOLOGY, 2013, 31 (01) : 70 - 75
  • [35] Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects
    Anne Gardin
    Cathy Gray
    Srikanth Neelakantham
    Felix Huth
    Antonia M. Davidson
    Swati Dumitras
    Eric Legangneux
    Kasra Shakeri-Nejad
    European Journal of Clinical Pharmacology, 2018, 74 : 1593 - 1604
  • [36] CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population
    Xiumei Hong
    Shanchun Zhang
    Guangyun Mao
    Shanqun Jiang
    Yan Zhang
    Yunxian Yu
    Genfu Tang
    Houxun Xing
    Xiping Xu
    European Journal of Clinical Pharmacology, 2005, 61 : 627 - 634
  • [37] Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects
    Gardin, Anne
    Gray, Cathy
    Neelakantham, Srikanth
    Huth, Felix
    Davidson, Antonia M.
    Dumitras, Swati
    Legangneux, Eric
    Shakeri-Nejad, Kasra
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (12) : 1593 - 1604
  • [38] Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers
    Shao, H.
    Ren, X. M.
    Liu, N. F.
    Chen, G. M.
    Li, W. L.
    Zhai, Z. H.
    Wang, D. W.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2010, 35 (03) : 351 - 360
  • [39] Effects of genetic variation at the CYP219/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians
    Janha, Ramatoulie E.
    Sisay-Joof, Fatoumatta
    Hamid-Adiamoh, Majidah
    Worwui, Archibald
    Chapman, Hannah L.
    Opara, Hyginus
    Dunyo, Sam
    Milligan, Paul
    Rockett, Kirk
    Winstanley, Peter
    Pirmohamed, Munir
    Miller, Ann K.
    Conway, David J.
    Walton, Robert T.
    PHARMACOGENOMICS, 2009, 10 (09) : 1423 - 1431
  • [40] Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects
    Zhang, Yifan
    Si, Dayong
    Chen, Xiaoyan
    Lin, Nan
    Guo, Yingjie
    Zhou, Hui
    Zhong, Dafang
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 64 (01) : 67 - 74
12345